COMPARE · Data as of August 27, 2026
BCS vs CM
Verdict: Side-by-side breakdown using the Bull Rankings model. BCS scored 76.0, CM scored 74.0 — BCS leads.
Compare another set
BCS
Barclays PLC
64.9Fin
$26.87 · $90.3B
Strength gap
2.2
BCS leads
CM
Canadian Imperial Bank of Commerce
62.7Fin
$114.84 · $104.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestBCS10.2x
- Fastest growthCM+13.7%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
Fundamentals, head-to-head
BCS
CM
+11.1%B
Rev
+13.7%B+
10.2xA-
P/E
15.8xC+
10.1%B
ROE
15.4%B+
1.01A-
P/B
2.27C+
2.3%B
Yield
2.6%B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
BCSBarclays PLC
Why now
Banks - Diversified · market cap $90.3b. 6% off the 52-week high of $28.69. Revenue growing +11%, comfortably above the S&P median. 4 sell-side analysts rate this a Buy with a mean 1-yr target of $30.27 (implying +13% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 10% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $90.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Credit-cycle exposure — provisions tend to lag actual loan deterioration by 2-3 quarters; a sharp uptick in net charge-offs is a leading indicator the market often misses until it's already priced.
CMCanadian Imperial Bank of Commerce
Why now
Banks - Diversified · market cap $104.3b. 8% off the 52-week high of $124.86. Revenue growing +14%, comfortably above the S&P median. 3 sell-side analysts rate this a Buy with a mean 1-yr target of $118.90 (implying +4% upside).
Moat
Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 15% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. $104.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.